期刊
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
卷 87, 期 1, 页码 114-124出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejpb.2013.12.015
关键词
Raloxifene HCl; Solid lipid nanoparticle; Box-Bhenken design; Design of experiments; Everted gut sac; Lymphatic transport; Glyceryl behenate
资金
- University Grants Commission (UGC), India [39-176/2010 (SR)]
Raloxifene HCI (RLX) shows low oral bioavailability (<2%) in humans due to poor aqueous solubility and extensive (>90%) metabolism in gut. Lipid nanoparticles (SLN) with glyceryl tribehenate were designed to enhance drug's oral bioavailability. Box-Bhenken design was used to optimize manufacturing conditions. Optimized SLN had particle size of 167 +/- 3 nm and high encapsulation efficiency (>92%). Oral bioavailability of RLX from SLN was improved by 3.24 folds compared to free RLX in female Wistar rats. Both clathrin and caveolae mediated endocytosis pathways were involved in the uptake of SLN. Lymphatic transport inhibitor, cycloheximide significantly reduced oral bioavailability of SLN. (C) 2014 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据